Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 35

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Triple negative breast cancer+4

Recruiting

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Central nervous system lymphoma

Recruiting

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Conjunctivitis allergic+3

Recruiting

Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Lepidoglyphus destructor Immunotherapy for Allergic Rhinitis and Rhinoconjunctivitis in Patients With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLERGEN EXTRACTS

Endometriosis

Recruiting

Letrozole During IVF/ICSI for Women with Endometriosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Letrozole

Acute promyelocytic leukaemia

Recruiting

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide

Multiple system atrophy

Recruiting

Open-Label Extension Study of ATH434-DP2 in Patients with Multiple System Atrophy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:5,7-DICHLORO-2-((ETHYLAMINO)METHYL)-8-HYDROXY-3-METHYLQUINAZOLIN-4(3H)-ONE METHANESULFONATE

Type IIa hyperlipidaemia

Recruiting

Lerodalcibep for Heterozygous Familial Hypercholesterolemia in Children and Adolescents 6 to 17 Years Old

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Lerodalcibep

Neuroendocrine carcinoma

Recruiting

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Oesophageal squamous cell carcinoma

Recruiting

Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.